CN107106615A - 胎盘来源的贴壁细胞外泌体及其用途 - Google Patents

胎盘来源的贴壁细胞外泌体及其用途 Download PDF

Info

Publication number
CN107106615A
CN107106615A CN201580054280.7A CN201580054280A CN107106615A CN 107106615 A CN107106615 A CN 107106615A CN 201580054280 A CN201580054280 A CN 201580054280A CN 107106615 A CN107106615 A CN 107106615A
Authority
CN
China
Prior art keywords
exosomes
placenta
derived adherent
mir
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580054280.7A
Other languages
English (en)
Chinese (zh)
Inventor
埃里克·劳
安德鲁·莫绍泽尔
亚历山大·弗兰茨基
詹妮弗·帕雷德斯
凯西·E·卡拉斯威茨-门德斯
艾伦·雷杜塔
弗拉基米尔·扬科维奇
伊凡娜·杜雷蒂克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clarity Acquisition II LLC
Original Assignee
Anthrogenesis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55653751&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107106615(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anthrogenesis Corp filed Critical Anthrogenesis Corp
Priority to CN202310711769.3A priority Critical patent/CN116731958A/zh
Publication of CN107106615A publication Critical patent/CN107106615A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/02—Coculture with; Conditioned medium produced by embryonic cells
    • C12N2502/025—Coculture with; Conditioned medium produced by embryonic cells extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201580054280.7A 2014-10-09 2015-10-08 胎盘来源的贴壁细胞外泌体及其用途 Pending CN107106615A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310711769.3A CN116731958A (zh) 2014-10-09 2015-10-08 胎盘来源的贴壁细胞外泌体及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462062046P 2014-10-09 2014-10-09
US62/062,046 2014-10-09
PCT/US2015/054629 WO2016057755A1 (en) 2014-10-09 2015-10-08 Placenta-derived adherent cell exosomes and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310711769.3A Division CN116731958A (zh) 2014-10-09 2015-10-08 胎盘来源的贴壁细胞外泌体及其用途

Publications (1)

Publication Number Publication Date
CN107106615A true CN107106615A (zh) 2017-08-29

Family

ID=55653751

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580054280.7A Pending CN107106615A (zh) 2014-10-09 2015-10-08 胎盘来源的贴壁细胞外泌体及其用途
CN202310711769.3A Pending CN116731958A (zh) 2014-10-09 2015-10-08 胎盘来源的贴壁细胞外泌体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310711769.3A Pending CN116731958A (zh) 2014-10-09 2015-10-08 胎盘来源的贴壁细胞外泌体及其用途

Country Status (8)

Country Link
US (3) US20170252379A1 (https=)
EP (1) EP3204022B1 (https=)
JP (3) JP2017536096A (https=)
CN (2) CN107106615A (https=)
AU (2) AU2015330855A1 (https=)
CA (1) CA2964114A1 (https=)
DK (1) DK3204022T3 (https=)
WO (1) WO2016057755A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110093274A (zh) * 2019-05-13 2019-08-06 山东大学 一种增加细胞产生的细胞外囊泡数量的挤压装置及其应用
WO2020125447A1 (zh) * 2018-12-18 2020-06-25 深圳先进技术研究院 无创超声处理细胞在制备外泌体中的应用、外泌体及其制备方法和应用
CN111433352A (zh) * 2017-11-16 2020-07-17 细胞结构公司 用以分离外泌体的胎盘培养
CN112384200A (zh) * 2018-01-30 2021-02-19 希斯托金公司 低氧条件下培养的细胞衍生的胞外囊泡及其用途
CN117050936A (zh) * 2023-07-11 2023-11-14 清华大学 新亚群的人脐带间充质干细胞、其外泌体、制剂和应用

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10900034B2 (en) 2014-12-03 2021-01-26 Agilent Technologies, Inc. Guide RNA with chemical modifications
EP3280803B1 (en) 2015-04-06 2021-05-26 The Board of Trustees of the Leland Stanford Junior University Chemically modified guide rnas for crispr/cas-mediated gene regulation
US20180177727A1 (en) 2015-06-10 2018-06-28 Board Of Regents, The University Of Texas System Use of exosomes for the treatment of disease
CA3023349A1 (en) * 2016-05-16 2017-11-23 Exostem Biotec Ltd. Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
AU2018266111B2 (en) 2017-05-08 2024-11-07 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
US20200163993A1 (en) * 2017-05-09 2020-05-28 Saint Louis University Treatment of cancer and infectious diseases with natural killer (nk) cell-derived exosomes
US20200188440A1 (en) * 2017-05-16 2020-06-18 Exostem Biotec Ltd. Methods of inhibiting aging and treating aging-related disorders
IL270864B2 (en) * 2017-05-24 2025-01-01 Nanosomix Inc Identification of biomarkers on vesicles for diagnosis and prognosis of diseases and disorders
KR102109950B1 (ko) * 2017-06-02 2020-05-12 (주)엑솔런스바이오테크놀로지 체외충격파를 이용한 세포외소포체 내로의 표적물질 전달방법
EP3672573A4 (en) 2017-08-25 2021-05-26 Codiak BioSciences, Inc. PREPARATION OF THERAPEUTIC EXOSOMES USING MEMBRANE PROTEINS
KR102335710B1 (ko) * 2017-10-31 2021-12-07 (주)아모레퍼시픽 유산균 유래의 세포밖 베지클을 포함하는 면역조절용 조성물
GB201718681D0 (en) * 2017-11-13 2017-12-27 Evox Therapeutics Ltd Protein engineered extracellular vesicles
WO2019118817A1 (en) * 2017-12-14 2019-06-20 Mayo Foundation For Medical Education And Research Purified exosome products, method of making, and methods of using
AU2018394238A1 (en) 2017-12-28 2020-06-18 Lonza Sales Ag Exosomes for immuno-oncology and anti-inflammatory therapy
KR102235141B1 (ko) * 2018-06-19 2021-04-05 푸와이 하스피틀, 차이니즈 아카데미 오브 메디컬 사이언시즈 앤드 페킹 유니언 메디컬 칼리지 약물 전처리에 기초한 간엽 줄기세포 유래 엑소좀 제조방법
AU2019312212B2 (en) * 2018-07-24 2024-10-10 Mayo Foundation For Medical Education And Research Compositions and methods involving transforming extracellular vesicles
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
PH12021553167A1 (en) * 2019-06-19 2022-08-15 Celularity Inc Exosomes for disease treatment
WO2021210852A1 (ko) * 2020-04-14 2021-10-21 (주)녹십자웰빙 태반 유래 물질을 포함하는 항바이러스 조성물
KR20220030552A (ko) * 2020-09-03 2022-03-11 (주)녹십자웰빙 태반 유래 엑소좀을 포함하는 간세포 증식 또는 항염증 효능 조성물
JP2024534945A (ja) 2021-09-10 2024-09-26 アジレント・テクノロジーズ・インク 化学修飾を有するプライム編集のためのガイドｒｎａ
WO2024102969A1 (en) * 2022-11-10 2024-05-16 Board Of Regents, The University Of Texas System Use of fecal derivatives and fecal derived extracellular vesicles to enhance immunity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130195899A1 (en) * 2012-01-31 2013-08-01 Medistem, Inc. Therapeutic immune modulation by stem cell secreted exosomes
WO2014022852A1 (en) * 2012-08-03 2014-02-06 Aptamir Therapeutics, Inc. Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2316918B1 (en) 2001-02-14 2015-07-01 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
PL2471907T3 (pl) 2005-12-29 2019-07-31 Celularity, Inc. Populacje komórek macierzystych łożyska
CA2734237C (en) 2008-08-20 2019-07-02 Anthrogenesis Corporation Treatment of stroke using isolated placental cells
RU2539786C2 (ru) * 2008-09-02 2015-01-27 Плуристем Лтд. Выращенные в прикрепленной к субстрату культуре клетки из ткани плаценты и их использование при лечении
GB2463401B (en) * 2008-11-12 2014-01-29 Caris Life Sciences Luxembourg Holdings S A R L Characterizing prostate disorders by analysis of microvesicles
FR2950360B1 (fr) * 2009-09-22 2011-11-25 Centre Nat Rech Scient Procede d'imagerie cellulaire pour la visualisation de la biogenese des microarns dans les cellules
DK2556145T3 (en) * 2010-04-07 2016-11-07 Anthrogenesis Corp Angiogenesis using placental stem cells
EP2691101A2 (en) * 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EP2721179A4 (en) * 2011-06-16 2014-10-01 Caris Life Sciences Luxembourg Holdings S A R L BIOMARKER COMPOSITIONS AND METHOD THEREFOR
US11391741B2 (en) * 2011-12-22 2022-07-19 Theoria Science Inc. Method of exosome analysis, reagent for exosome analysis, and analyzer for exosome
AU2013302799B2 (en) * 2012-08-13 2018-03-01 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
DK2931897T3 (en) * 2012-12-12 2018-02-05 Broad Inst Inc CONSTRUCTION, MODIFICATION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTICAL APPLICATIONS
EP2935628B1 (en) * 2012-12-19 2018-03-21 Caris Life Sciences Switzerland Holdings GmbH Compositions and methods for aptamer screening
EP3608022A1 (en) * 2013-03-15 2020-02-12 The Trustees of Princeton University Methods and devices for high throughput purification

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130195899A1 (en) * 2012-01-31 2013-08-01 Medistem, Inc. Therapeutic immune modulation by stem cell secreted exosomes
WO2014022852A1 (en) * 2012-08-03 2014-02-06 Aptamir Therapeutics, Inc. Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CEREN KORKUT ET AL.: "Regulation of Postsynaptic Retrograde Signaling by Presynaptic Exosome Release", 《NEURON》 *
卢婉等: "外泌体的研究进展", 《生命的化学》 *
沙文琼等: "人胚胎滋养细胞和胎盘间充质干细胞的分离与纯化", 《中国组织工程研究与临床康复》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111433352A (zh) * 2017-11-16 2020-07-17 细胞结构公司 用以分离外泌体的胎盘培养
CN112384200A (zh) * 2018-01-30 2021-02-19 希斯托金公司 低氧条件下培养的细胞衍生的胞外囊泡及其用途
WO2020125447A1 (zh) * 2018-12-18 2020-06-25 深圳先进技术研究院 无创超声处理细胞在制备外泌体中的应用、外泌体及其制备方法和应用
CN110093274A (zh) * 2019-05-13 2019-08-06 山东大学 一种增加细胞产生的细胞外囊泡数量的挤压装置及其应用
CN117050936A (zh) * 2023-07-11 2023-11-14 清华大学 新亚群的人脐带间充质干细胞、其外泌体、制剂和应用

Also Published As

Publication number Publication date
AU2021204332A1 (en) 2021-07-22
JP2023011580A (ja) 2023-01-24
JP2017536096A (ja) 2017-12-07
DK3204022T3 (da) 2021-03-08
EP3204022A1 (en) 2017-08-16
WO2016057755A1 (en) 2016-04-14
US20170252379A1 (en) 2017-09-07
US11173182B1 (en) 2021-11-16
EP3204022B1 (en) 2020-12-02
CA2964114A1 (en) 2016-04-14
EP3204022A4 (en) 2018-06-13
AU2015330855A1 (en) 2017-04-27
CN116731958A (zh) 2023-09-12
US20220241347A1 (en) 2022-08-04
JP2021040635A (ja) 2021-03-18

Similar Documents

Publication Publication Date Title
US11173182B1 (en) Placenta-derived adherent cell exosomes and uses thereof
US20230310319A1 (en) Cultivation of placenta to isolate exosomes
JP6716564B2 (ja) 安定したエクソソーム製剤の製造方法
US20220096560A1 (en) Methods and compositions relating to mesenchymal stem cell exosomes
US20230181649A1 (en) Exosomes for disease treatment
KR20210061328A (ko) 중간엽 줄기 세포로부터 유래된 세포외 소포
CN115710574A (zh) 用于医学的人血小板裂解物来源细胞外囊泡
US20230143893A1 (en) Isolation and purification of exosomes for regenerative medicine
WO2023164241A1 (en) Method for enriching muse cells and obtaining exosomes, microvesicles or the secretome therefrom
CN111182890A (zh) 用于治疗大疱性表皮松解症的方法和组合物
WO2015076717A2 (en) Mscs in the treatment of cardiac disorders
WO2021200299A1 (ja) 細胞老化抑制剤、生体組織修復促進剤、遺伝子発現調節剤及び製造方法
JP2024507587A (ja) 制御性Ｔ細胞（Ｔｒｅｇ）細胞外小胞組成物及び方法
EP4123019A1 (en) Cord blood plasma-derived exosome or mimetic thereof and pharmaceutical use thereof
HK1241290A1 (en) Placenta-derived adherent cell exosomes and uses thereof
HK1242969B (en) Placenta-derived adherent cell exosomes and uses thereof
HK1242969A1 (en) Placenta-derived adherent cell exosomes and uses thereof
US20230414673A1 (en) Extracellular vesicles derived from cardiosphere-derived cells as anti-shock therapeutics
IL281185B2 (en) Treatment of diabetic peripheral neuropathy using placental cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1241290

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20220728

Address after: new jersey

Applicant after: ANTHROGENESIS Corp.

Address before: new jersey

Applicant before: ANTHROGENESIS Corp.

TA01 Transfer of patent application right
RJ01 Rejection of invention patent application after publication

Application publication date: 20170829

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1241290

Country of ref document: HK